Preclina

Preclina isSouth Korean non-clinical CRO specializing in drug discovery research for autoimmune and inflammatory diseasesWe handle everything in-house, from efficacy evaluation using patient-derived cells and disease models to pathological analysis, PK/ADME, and toxicity evaluation.

Features of Preclina's non-clinical contract testing services

disease models specialized in autoimmune and inflammatory diseases

Preclina isEfficacy evaluation of drugs for autoimmune and inflammatory diseasesWe are a CRO specializing in [insert area of expertise], conducting evaluations using disease-mimicking animal models for conditions such as arthritis, fibrosis, inflammatory skin diseases, inflammatory bowel disease, neurological disorders, and connective tissue diseases. By accumulating research experience focused on specific disease areas, we make it easy to establish tailored evaluation systems suited to your objectives when examining the efficacy and mechanisms of action of candidate substances.

Utilizing patient-derived cells and humanized mice

In cell-based assays,primary cells derived from patients with autoimmune diseasesWe support cell-based assays using . Furthermore, we have developed a Humanized Mouse Platform utilizing PBMC and CD34+ hematopoietic stem cells. Using models such as PreHu™-P and PreHu™-H, we provide an evaluation environment for next-generation immune therapeutics, including antibody drugs, ADCs, CAR-T/NK, and bispecific antibodies.

From efficacy evaluation to pathology, PK/ADME, and toxicity

Not only efficacy tests,Histopathology, DMPK & ADME, ToxicologyWe also undertake such peripheral evaluations. In the pathology field, in addition to standard histological analyses, we offer disease-specific custom analyses and pathology consulting. We also conduct evaluations combining PK/PD analysis and efficacy studies, establishing a system capable of advancing a series of research stages from candidate compound screening to Lead Optimization and Confirmative Trials. Please note that since information indicating GLP compliance is not confirmed on the official website, prior confirmation is necessary if GLP-compliant studies are required.

An example of a disease model owned by Preclina

At Preclina, we develop various disease models focusing on autoimmune and inflammatory diseases. For example, in pulmonary fibrosis,Bleomycin-induced Lung Fibrosis (BILF) modelDeploying the Humanized BILF model. It also supports quantitative evaluation of lung conditions using Micro-CT, making it applicable for evaluating the efficacy of anti-fibrotic drug candidates.

Preclina non-clinical study cases

Evaluation of candidate compounds using a pulmonary fibrosis model

In the field of pulmonary fibrosis, PreclinaEfficacy evaluation using mouse and rat disease modelsis being conducted. The official website introduces research examples combining everything from screening to Lead Optimization and Confirmative Trial. A key feature is the ability to quantitatively evaluate the overall lung condition, percentage of lung infiltration, and volume changes using Micro-CT, allowing for a multifaceted examination of candidate compound effects. In addition, the Humanized BILF model is also developed and provided.

Preclina company information